



SAFETY DATA SHEET

Revision Date 21-Oct-2020

Revision Number 1

**100-0583 100-0584 - Anti-SARS-CoV-2 Spike Protein S1
Receptor Binding Domain Antibody, Clone Covi-1
(Blocking/Recombinant)**

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

Product identifier

Product Name Anti-SARS-CoV-2 Spike Protein S1 Receptor Binding Domain Antibody, Clone Covi-1
(Blocking/Recombinant)

Other means of identification

Catalog Number 100-0583 100-0584

Document Number 10000009169

Synonyms None

Recommended use of the chemical and restrictions on use

Recommended Use Laboratory reagent

Details of the supplier of the safety data sheet

Manufacturer/Supplier

STEMCELL Technologies Canada Inc.
Suite 500 - 1618 Station Street
Vancouver, British Columbia V6A 1B6 Canada

Emergency telephone number

Emergency Telephone 1-800-667-0322

2. HAZARDS IDENTIFICATION

Classification

This chemical is not considered hazardous by the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200)

Hazards not otherwise classified (HNOC)

Not applicable

Label elements



SAFETY DATA SHEET

**100-0583 100-0584 - Anti-SARS-CoV-2 Spike Protein S1
Receptor Binding Domain Antibody, Clone Covi-1
(Blocking/Recombinant)**

Revision Date 21-Oct-2020

Revision Number 1

Hazard statements

Not a hazardous substance or mixture according to the Globally Harmonized System (GHS)

The product contains no substances which at their given concentration, are considered to be hazardous to health.

Appearance Clear

Physical state Liquid

Odor No information available

Other Information

Not applicable

Unknown acute toxicity 0 % of the mixture consists of ingredient(s) of unknown toxicity

0 % of the mixture consists of ingredient(s) of unknown acute oral toxicity

0 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity

0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (gas)

0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (vapor)

0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist)

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance

Not applicable.

Mixture

Not a hazardous substance or mixture according to the Globally Harmonized System (GHS)

*The exact percentage (concentration) of composition has been withheld as a trade secret.

4. FIRST AID MEASURES

Description of first aid measures

Inhalation Remove to fresh air.

Eye contact Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids.



SAFETY DATA SHEET

Revision Date 21-Oct-2020

Revision Number 1

**100-0583 100-0584 - Anti-SARS-CoV-2 Spike Protein S1
Receptor Binding Domain Antibody, Clone Covi-1
(Blocking/Recombinant)**

Consult a physician.

Skin contact

Wash skin with soap and water.

Ingestion

Clean mouth with water and drink afterwards plenty of water.

Most important symptoms and effects, both acute and delayed**Symptoms**

No information available.

Indication of any immediate medical attention and special treatment needed**Note to physicians**

Treat symptomatically.

5. FIRE-FIGHTING MEASURES

Suitable Extinguishing Media

Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Unsuitable extinguishing media

CAUTION: Use of water spray when fighting fire may be inefficient.

Specific hazards arising from the chemical

No information available.

Explosion data

Sensitivity to Mechanical Impact None.

Sensitivity to Static Discharge None.

Special protective equipment for fire-fighters

Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures**Personal precautions**

Ensure adequate ventilation.

Environmental precautions**Environmental precautions**

See Section 12 for additional Ecological Information.



SAFETY DATA SHEET

Revision Date 21-Oct-2020

Revision Number 1

**100-0583 100-0584 - Anti-SARS-CoV-2 Spike Protein S1
Receptor Binding Domain Antibody, Clone Covi-1
(Blocking/Recombinant)**

Methods and material for containment and cleaning up

Methods for containment	Prevent further leakage or spillage if safe to do so.
Methods for cleaning up	Pick up and transfer to properly labeled containers.
Prevention of secondary hazards	Clean contaminated objects and areas thoroughly observing environmental regulations.

7. HANDLING AND STORAGE

Precautions for safe handling

Advice on safe handling Handle in accordance with good industrial hygiene and safety practice.

Conditions for safe storage, including any incompatibilities

Storage Conditions Store in accordance with information listed on the Product Information Sheet (PIS).

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Control parameters

Exposure Limits This product, as supplied, does not contain any hazardous materials with occupational exposure limits established by the region specific regulatory bodies.

Appropriate engineering controls

Engineering controls Showers
Eyewash stations
Ventilation systems.

Individual protection measures, such as personal protective equipment

Eye/face protection No special protective equipment required.

Skin and body protection No special protective equipment required.

Respiratory protection No protective equipment is needed under normal use conditions. If exposure limits are



SAFETY DATA SHEET

Revision Date 21-Oct-2020

Revision Number 1

**100-0583 100-0584 - Anti-SARS-CoV-2 Spike Protein S1
Receptor Binding Domain Antibody, Clone Covi-1
(Blocking/Recombinant)**

exceeded or irritation is experienced, ventilation and evacuation may be required.

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

9. PHYSICAL AND CHEMICAL PROPERTIES

Information on basic physical and chemical properties

Physical state	Liquid
Appearance	Clear
Color	No information available
Odor	No information available
Odor threshold	No information available

<u>Property</u>	<u>Values</u>	<u>Remarks • Method</u>
pH	No data available	None known
Melting point / freezing point	No data available	None known
Boiling point / boiling range	No data available	None known
Flash point	No data available	None known
Evaporation rate	No data available	None known
Flammability (solid, gas)	No data available	None known
Flammability Limit in Air		None known
Upper flammability limit:	No data available	
Lower flammability limit:	No data available	
Vapor pressure	No data available	None known
Vapor density	No data available	None known
Relative density	No data available	None known
Water solubility	No data available	None known
Solubility in other solvents	No data available	None known
Partition coefficient	No data available	None known
Autoignition temperature	No data available	None known
Decomposition temperature	No data available	None known
Kinematic viscosity	No data available	None known
Dynamic viscosity	No data available	None known
Explosive properties	No information available	
Oxidizing properties	No information available	

Other Information

Softening point	No information available
Molecular weight	No information available
Molecular formula	No information available
VOC Content (%)	No information available
Liquid Density	No information available
Bulk density	No information available



SAFETY DATA SHEET

Revision Date 21-Oct-2020

Revision Number 1

**100-0583 100-0584 - Anti-SARS-CoV-2 Spike Protein S1
Receptor Binding Domain Antibody, Clone Covi-1
(Blocking/Recombinant)**

10. STABILITY AND REACTIVITY

Reactivity	No information available.
Chemical stability	Stable under normal conditions.
Possibility of hazardous reactions	None under normal processing.
Conditions to avoid	None known based on information supplied.
Incompatible materials	None known based on information supplied.
Hazardous decomposition products	None known based on information supplied.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Product Information

Inhalation	Specific test data for the substance or mixture is not available.
Eye contact	Specific test data for the substance or mixture is not available.
Skin contact	Specific test data for the substance or mixture is not available.
Ingestion	Specific test data for the substance or mixture is not available.

Symptoms related to the physical, chemical and toxicological characteristics

Symptoms	No information available.
-----------------	---------------------------

Numerical measures of toxicity

Acute toxicity

Unknown acute toxicity	0 % of the mixture consists of ingredient(s) of unknown toxicity
	0 % of the mixture consists of ingredient(s) of unknown acute oral toxicity
	0 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity
	0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (gas)
	0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (vapor)
	0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist)



SAFETY DATA SHEET

Revision Date 21-Oct-2020

Revision Number 1

**100-0583 100-0584 - Anti-SARS-CoV-2 Spike Protein S1
Receptor Binding Domain Antibody, Clone Covi-1
(Blocking/Recombinant)**

Delayed and immediate effects as well as chronic effects from short and long-term exposure

Skin corrosion/irritation	No information available.
Serious eye damage/eye irritation	No information available.
Respiratory or skin sensitization	No information available.
Germ cell mutagenicity	No information available.
Carcinogenicity	No information available.
Reproductive toxicity	No information available.
STOT - single exposure	No information available.
STOT - repeated exposure	No information available.
Aspiration hazard	No information available.

12. ECOLOGICAL INFORMATION

Ecotoxicity	.
Persistence and degradability	No information available.
Bioaccumulation	There is no data for this product.
Other adverse effects	No information available.

13. DISPOSAL CONSIDERATIONS

Waste treatment methods

Waste from residues/unused products	Dispose of in accordance with local regulations. Dispose of waste in accordance with environmental legislation.
Contaminated packaging	Do not reuse empty containers.



SAFETY DATA SHEET

Revision Date 21-Oct-2020

Revision Number 1

**100-0583 100-0584 - Anti-SARS-CoV-2 Spike Protein S1
Receptor Binding Domain Antibody, Clone Covi-1
(Blocking/Recombinant)**

14. TRANSPORT INFORMATION

<u>DOT</u>	Not regulated
<u>TDG</u>	Not regulated
<u>MEX</u>	Not regulated
<u>ICAO (air)</u>	Not regulated
<u>IATA</u>	Not regulated
<u>IMDG</u>	Not regulated
<u>RID</u>	Not regulated
<u>ADR</u>	Not regulated
<u>ADN</u>	Not regulated

15. REGULATORY INFORMATION

International Inventories

TSCA	Complies
DSL/NDSL	Complies
EINECS/ELINCS	Complies
ENCS	Does not comply
IECSC	Complies
KECL	Complies
PICCS	Complies
AICS	Complies

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

ENCS - Japan Existing and New Chemical Substances

IECSC - China Inventory of Existing Chemical Substances

KECL - Korean Existing and Evaluated Chemical Substances

PICCS - Philippines Inventory of Chemicals and Chemical Substances

AICS - Australian Inventory of Chemical Substances

US Federal Regulations



SAFETY DATA SHEET

Revision Date 21-Oct-2020

Revision Number 1

**100-0583 100-0584 - Anti-SARS-CoV-2 Spike Protein S1
Receptor Binding Domain Antibody, Clone Covi-1
(Blocking/Recombinant)**

SARA 313

Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40 of the Code of Federal Regulations, Part 372.

SARA 311/312 Hazard Categories

Acute health hazard	No
Chronic Health Hazard	No
Fire hazard	No
Sudden release of pressure hazard	No
Reactive Hazard	No

CWA (Clean Water Act)

This product does not contain any substances regulated as pollutants pursuant to the Clean Water Act (40 CFR 122.21 and 40 CFR 122.42).

CERCLA

This material, as supplied, does not contain any substances regulated as hazardous substances under the Comprehensive Environmental Response Compensation and Liability Act (CERCLA) (40 CFR 302) or the Superfund Amendments and Reauthorization Act (SARA) (40 CFR 355). There may be specific reporting requirements at the local, regional, or state level pertaining to releases of this material.

US State Regulations

California Proposition 65

This product does not contain any Proposition 65 chemicals.

U.S. State Right-to-Know Regulations

US State Regulations

Chemical name	New Jersey	Massachusetts	Pennsylvania
Water 7732-18-5	-	-	X
Sodium Phosphate Dibasic 7558-79-4	X	X	X

U.S. EPA Label Information

EPA Pesticide Registration Number Not applicable



SAFETY DATA SHEET

**100-0583 100-0584 - Anti-SARS-CoV-2 Spike Protein S1
Receptor Binding Domain Antibody, Clone Covi-1
(Blocking/Recombinant)**

Revision Date 21-Oct-2020

Revision Number 1

16. OTHER INFORMATION, INCLUDING DATE OF PREPARATION OF THE LAST REVISION

Prepared By, Quality Control. STEMCELL Technologies Canada Inc.

Revision Date 21-Oct-2020

Revision Note No information available.

Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text. STEMCELL Technologies Inc. shall not be held liable for any damage resulting from handling or from contact with the product.

End of Safety Data Sheet